Prostate Cancer

Karim Fizazi, MD, PhD, discusses the potential role for darolutamide in combination with androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer.

PET imaging modalities such as fluciclovine PET, choline PET, and more recently PSMA-PET are more sensitive in the detection of both soft tissue and bone metastases. These newer modalities have the potential to better identify patients who are eligible for targeted treatment of oligometastases with radiation or treatments more appropriate for immediate systemic androgen deprivation, according to Arjun V. Balar, MD.

Olaparib demonstrated a statistically significant improvement in radiographic progression-free survival compared with enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair mutation and have progressed on prior treatment with new hormonal anticancer treatments, according to early findings from the PROfound trial.

Take a look back on the FDA happenings, including approvals, fast track designations, priority reviews, and more from the month of July 2019.

Darolutamide has been approved by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer. 

Evan Y. Yu, MD, discussed the key takeaways from the phase Ib/II KEYNOTE-365 trial, which evaluated different novel pembrolizumab (Keytruda) combinations in patients with metastatic castration-resistant prostate cancer.

Testosterone suppression with docetaxel, the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), was combined with chemotherapy or enzalutamide (Xtandi) to assess the potential improvement in overall survival compared with non-steroidal anti-androgens like bicalutamide, nilutamide, and flutamide in the&nbsp;phase III ENZAMET trial.&nbsp;<br /> &nbsp;

Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine,&nbsp;Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer, recently presented during the 2019 ASCO Annual Meeting.&nbsp;<br /> &nbsp;

General Cancer

A study aimed at exploring genomic diversity and defining its associations with clinical outcomes in metastatic castration-resistant prostate cancer found that alterations in&nbsp;RB1&nbsp;were a potent predictor of poor survival and that other common aberrations may serve as prognostic indicators of treatment response, according to recent work published in the&nbsp;Proceedings of the National Academy of Sciences.